Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

Research output: Contribution to journalArticlepeer-review

Standard

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study. / Kumar, S K; Lee, J H; Lahuerta, J J; Morgan, G; Richardson, P G; Crowley, J; Haessler, J; Feather, J; Hoering, A; Moreau, P; LeLeu, X; Hulin, C; Klein, S K; Sonneveld, P; Siegel, D; Bladé, J; Goldschmidt, H; Jagannath, S; Miguel, J S; Orlowski, R; Palumbo, A; Sezer, O; Rajkumar, S V; Durie, B G M; IMWG ; Wheatley, Keith.

In: Leukemia, Vol. 26, No. 1, 01.2012, p. 149-57.

Research output: Contribution to journalArticlepeer-review

Harvard

Kumar, SK, Lee, JH, Lahuerta, JJ, Morgan, G, Richardson, PG, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, SK, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, JS, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, SV, Durie, BGM, IMWG & Wheatley, K 2012, 'Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study', Leukemia, vol. 26, no. 1, pp. 149-57. https://doi.org/10.1038/leu.2011.196

APA

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., LeLeu, X., Hulin, C., Klein, S. K., Sonneveld, P., Siegel, D., Bladé, J., Goldschmidt, H., Jagannath, S., Miguel, J. S., ... Wheatley, K. (2012). Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia, 26(1), 149-57. https://doi.org/10.1038/leu.2011.196

Vancouver

Author

Kumar, S K ; Lee, J H ; Lahuerta, J J ; Morgan, G ; Richardson, P G ; Crowley, J ; Haessler, J ; Feather, J ; Hoering, A ; Moreau, P ; LeLeu, X ; Hulin, C ; Klein, S K ; Sonneveld, P ; Siegel, D ; Bladé, J ; Goldschmidt, H ; Jagannath, S ; Miguel, J S ; Orlowski, R ; Palumbo, A ; Sezer, O ; Rajkumar, S V ; Durie, B G M ; IMWG ; Wheatley, Keith. / Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study. In: Leukemia. 2012 ; Vol. 26, No. 1. pp. 149-57.

Bibtex

@article{08ed3838f8194061a191d8fe404b15f6,
title = "Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study",
abstract = "Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T(0)). The median age at diagnosis was 58 years, and time from diagnosis to T(0) was 3.3 years. Following T(0), 213 (74%) patients had a treatment recorded with one or more regimens (median=1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T(0) in 94 patients (44%) including ≥ partial response in 69 (32%). The median overall survival and event-free survival from T(0) were 9 and 5 months, respectively. This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs.",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Disease Progression, Female, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Survival Analysis",
author = "Kumar, {S K} and Lee, {J H} and Lahuerta, {J J} and G Morgan and Richardson, {P G} and J Crowley and J Haessler and J Feather and A Hoering and P Moreau and X LeLeu and C Hulin and Klein, {S K} and P Sonneveld and D Siegel and J Blad{\'e} and H Goldschmidt and S Jagannath and Miguel, {J S} and R Orlowski and A Palumbo and O Sezer and Rajkumar, {S V} and Durie, {B G M} and IMWG and Keith Wheatley",
year = "2012",
month = jan,
doi = "10.1038/leu.2011.196",
language = "English",
volume = "26",
pages = "149--57",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib

T2 - a multicenter international myeloma working group study

AU - Kumar, S K

AU - Lee, J H

AU - Lahuerta, J J

AU - Morgan, G

AU - Richardson, P G

AU - Crowley, J

AU - Haessler, J

AU - Feather, J

AU - Hoering, A

AU - Moreau, P

AU - LeLeu, X

AU - Hulin, C

AU - Klein, S K

AU - Sonneveld, P

AU - Siegel, D

AU - Bladé, J

AU - Goldschmidt, H

AU - Jagannath, S

AU - Miguel, J S

AU - Orlowski, R

AU - Palumbo, A

AU - Sezer, O

AU - Rajkumar, S V

AU - Durie, B G M

AU - IMWG

AU - Wheatley, Keith

PY - 2012/1

Y1 - 2012/1

N2 - Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T(0)). The median age at diagnosis was 58 years, and time from diagnosis to T(0) was 3.3 years. Following T(0), 213 (74%) patients had a treatment recorded with one or more regimens (median=1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T(0) in 94 patients (44%) including ≥ partial response in 69 (32%). The median overall survival and event-free survival from T(0) were 9 and 5 months, respectively. This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs.

AB - Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were refractory to bortezomib and were relapsed following, refractory to or ineligible to receive, an IMiD (immunomodulatory drug), had measurable disease, and ECOG PS of 0, 1 or 2. The date patients satisfied the entry criteria was defined as time zero (T(0)). The median age at diagnosis was 58 years, and time from diagnosis to T(0) was 3.3 years. Following T(0), 213 (74%) patients had a treatment recorded with one or more regimens (median=1; range 0-8). The first regimen contained bortezomib in 55 (26%) patients and an IMiD in 70 (33%). A minor response or better was seen to at least one therapy after T(0) in 94 patients (44%) including ≥ partial response in 69 (32%). The median overall survival and event-free survival from T(0) were 9 and 5 months, respectively. This study confirms the poor outcome, once patients become refractory to current treatments. The results provide context for interpreting ongoing trials of new drugs.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Disease Progression

KW - Female

KW - Humans

KW - Immunologic Factors

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Recurrence

KW - Survival Analysis

U2 - 10.1038/leu.2011.196

DO - 10.1038/leu.2011.196

M3 - Article

C2 - 21799510

VL - 26

SP - 149

EP - 157

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -